Buscar en
Enfermedades Infecciosas y Microbiología Clínica (English Edition)
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica (English Edition) Activity of Artemisia annua infusions on epimastigotes of Trypanosoma cruzi
Journal Information
Vol. 35. Issue 6.
Pages 390-392 (June - July 2017)
Vol. 35. Issue 6.
Pages 390-392 (June - July 2017)
Scientific letter
Full text access
Activity of Artemisia annua infusions on epimastigotes of Trypanosoma cruzi
Actividad de infusiones de Artemisia annua sobre epimastigotes de Trypanosoma cruzi
Visits
3586
Mariolga Berrizbeitia de Morgadoa,b,
Corresponding author
mberriz@yahoo.com

Corresponding author.
, Yusmaris Cariaco Sifontesc, José Imery Buizad, Pierre Lutgene
a Applied Biology, Sucre Nucleus, Universidad de Oriente, Cumaná, Sucre State, Venezuela
b Institute of Biomedical Research and Applied Sciences, Universidad de Oriente, Cumaná, Sucre State, Venezuela
c Bioanalysis Department, Sucre Nucleus, Universidad de Oriente, Cumaná, Sucre State, Venezuela
d Biology Department, Sucre Nucleus, Universidad de Oriente, Cumaná, Sucre State, Venezuela
e IFBV-BELHERB, Niederanven, Luxembourg
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text

Chagas disease is an anthropozoonosis caused by the flagellate protozoan Trypanosoma cruzi (T. cruzi).1 Currently, the treatment against T. cruzi is restricted to two drugs of limited effectiveness and high toxicity: benznidazole and nifurtimox.2 Therefore, it is necessary to find new therapeutic tools. The use of natural products such as Artemisia annua (A. annua) represents a novel choice; its active compound is artemisinin, a sesquiterpenoid lactone that crosses the biological membranes.3 This study evaluated the effect of the A. annua infusion on epimastigotes of T. cruzi.

Epimastigotes of T. cruzi were used (isolated: RHO/Ve/03/RG1 and CHHP). For the preparation of the infusions, dry and crushed A. annua leaves from 2 different origins were used: from plants grown in Cumaná (Venezuela) and in Luxembourg. The infusions were prepared at concentrations of 0.4, 0.6, 0.8, 1.0, 2.0 and 3.0% m/v of dry leaves of A. annua in the Liver Infusion Tryptose (LIT) culture medium.4 The experiments were performed by adjusting the cultures to a cellular density of 2×106 parasites/ml, in the various, previously described concentrations of the A. annua infusion. The trials were performed in triplicate and a control culture was included. The cellular viability of the epimastigotes of T. cruzi, was determined by the trypan blue dye exclusion method.5 In order to determine the effect of the A. annua infusion concentration on the growth of epimastigotes of T. cruzi, a multivariate analysis of variance was used.

The infusions of A. annua from Cumaná and Luxembourg had, at all concentrations tested, a dose-dependent antiproliferative effect on both isolates of T. cruzi studied, compared to the control culture. At the end of treatment (7th day) it was found that the concentrations that produced a greater inhibition of the growth were 2% and 3%; likewise, it was observed that the infusions of A. annua from Luxembourg had a more potent effect on parasite inhibition compared to infusions of plants grown in Cumaná, Venezuela (Fig. 1). This fact was confirmed by evaluating the minimum inhibitory concentration (MIC) in the various experiments, finding that the MIC of the Luxembourg-RG1 treatment was 2.6 times lower than that of the Cumaná-RG1 treatment; meanwhile the MIC of the Luxembourg-CHHP treatment was two times lower than that of the Cumaná-CHHP treatment. The multivariate analysis of variance revealed that the effect of infusions on the cellular density of epimastigotes of T. cruzi was exerted in a highly significant manner (p<0.001) depending on the type of infusion, concentration and time of exposure, and not significant for the different isolates evaluated. Regarding the incubation time of the cultures in the A. annua infusion, significant differences were found between days 0, 1, 2, 3 and 5 compared to day 7, indicating that the first days of treatment are key in the active inhibition of the epimastigotes of T. cruzi. During the course of treatment, the epimastigotes gradually lost their mobility, changing their typical fusiform morphology to an elongated and thin or rounded form, without flagella.

Fig. 1.

Activity of Artemisia annua infusion on epimastigotes of Trypanosoma cruzi. (A) Treatment using plant grown in Luxembourg on isolated CHHP. (B) Treatment using plant grown in Cumaná, Venezuela on isolated CHHP. (C) Treatment using plant grown in Luxembourg on isolated RG1. (D) Treatment using plant grown in Cumaná, Venezuela on isolated RG1.

(0.24MB).

This is the first study demonstrating the antiproliferative effect of A. annua on Venezuelan isolates of T. cruzi. Other authors have tested the antiproliferative effects of purified artemisinin on T. cruzi and T. brucei rhodesiense.6 The greater antiproliferative effect of the infusion prepared with the plant from Luxembourg could be due to the different production of active compounds and essential oils of both plants, which varies depending on the geographical origin of the plant and on the temperature.7 High ambient temperatures, such as is the case in Cumaná, Venezuela, produce a decrease in artemisinin concentrations.8 Also, the fact that A. annua infusions exerted their antiproliferative effect during the 7 days of treatment suggests that the other compounds present in the infusion could act synergistically as a combination therapy to perform their antiproliferative action.9

The results obtained in this study open up new research perspectives on the trypanocidal action of A. annua on T. cruzi, and offer a therapeutic alternative to be studied for the treatment of infection by this parasite.

References
[1]
World Health Organization.
Expert Committee on the Control of Chagas Disease.
(2002),
Available from: http://apps.who.int/iris/handle/10665/42443?locale=es [accessed 14.4.13]
[2]
J.R. Cancado.
Criteria of Chagas disease cure.
Mem Inst Oswaldo Cruz, 1 (1999), pp. 331-335
[3]
X. Luo, C. Shen.
The chemistry, pharmacology, and clinical application of qinghaosu (artemisinin) and its derivatives.
Med Res Rev, 7 (1987), pp. 29-52
[4]
M. Berrizbietia, M. Ndao, M. Gottschalk, A. Aché, F. Vásquez, S. Lacouture, et al.
Development and comparison of enzyme immunoassays for diagnosis of Chagas’ disease using fixed forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and assessment of antigen stability for the three assays.
J Clin Microbiol, 42 (2004), pp. 1766-1769
[5]
J. Kucsera, K. Yarita, K. Takeo.
Simple detection method for distinguishing dead and living yeast colonies.
J Microbiol Methods, 41 (2000), pp. 19-21
[6]
Y.V. Mishina, S. Krishna, R.K. Haynes, J.C. Meade.
Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.
Antimicrob Agents Chemother, 51 (2007), pp. 1852-1854
[7]
P. Engeu, F. Omujal, M. Agwaya, H. Kyakulaga, C. Obua.
Variations in antimalarial components of Artemisia annua Linn from three regions of Uganda.
Afr Health Sci, 15 (2015), pp. 828-834
[8]
J.F. Ferreira, J.E. Simon, J. Janick.
Developmental studies of Artemisia annua: flowering and artemisinin production under greenhouse and field conditions.
Planta Med, 61 (1995), pp. 167-170
[9]
K.C. Liu, S.L. Yang, M.F. Roberts, B.C. Elford, J.D. Phillipson.
Antimalarial activity of Artemisia annua flavonoids from whole plants and cell cultures.
Plant Cell Rep, 11 (1992), pp. 637-640

Please cite this article as: Berrizbeitia de Morgado M, Cariaco Sifontes Y, Imery Buiza J, Lutgen P. Actividad de infusiones de Artemisia annua sobre epimastigotes de Trypanosoma cruzi. Enferm Infecc Microbiol Clin. 2017;35:390–392.

Copyright © 2016. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos